Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England

Pharmacoecon Open. 2019 Mar;3(1):127. doi: 10.1007/s41669-018-0096-x.

Abstract

The second Key Point for Decision Makers, which reads.

Publication types

  • Published Erratum